The latest update is out from CASI Pharmaceuticals ( (CASI) ).
On April 7, 2025, CASI Pharmaceuticals announced the voluntary dismissal of a lawsuit filed by Acrotech Biopharma Inc. in New York, related to a dispute over the termination of a License Agreement for the commercialization of Evomela® in China. The case has now moved to arbitration with the American Arbitration Association. The outcome of the arbitration proceedings remains uncertain, but CASI is committed to protecting its legal rights.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
CASI Pharmaceuticals struggles with declining financial performance, high leverage, and negative cash flow trends. The technical picture shows a bearish trend, as the stock is trading below key moving averages. The valuation is unattractive due to a negative P/E ratio and no dividend yield, further detracting from the stock’s appeal.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and globally. The company specializes in hematology oncology therapeutics, organ transplant rejection, autoimmune disease, and other areas of unmet medical need. CASI aims to become a leader in the Greater China market by leveraging its regulatory and commercial competencies and global drug development expertise.
YTD Price Performance: -31.54%
Average Trading Volume: 13,465
Technical Sentiment Signal: Strong Buy
Current Market Cap: $31.14M
For detailed information about CASI stock, go to TipRanks’ Stock Analysis page.